SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syngene International concludes acquisition of biologics manufacturing facility

02 Dec 2023 Evaluate

Syngene International has concluded acquisition of multi-modal biologics manufacturing facility from Stelis Biopharma. The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crore adjusted from the earlier gross value of Rs 702 crore. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma.

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit - an essential capability for drug product manufacturing.

The unit has been acquired effective December 01, 2023 on payment of Rs 395 crore. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma.

Syngene International is India’s largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides. 

Syngene Internation. Share Price

458.00 -11.40 (-2.43%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 458.00
Indegene 529.65
CMS Info Systems 290.00
JITF Infralogistics 307.90
Sagility 44.18
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×